Rockefeller Capital Management
IOVA icon

Rockefeller Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Rockefeller Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$291K Sell
19,614
-15,368
-44% -$110K ﹤0.01% 2450
2026
Q2 		$146K Sell
34,982
-20,486
-37% -$77.8K ﹤0.01% 2770
2026
Q1 		$195K Buy
55,468
+4,742
+9% +$15.2K ﹤0.01% 2513
2025
Q4 		$138K Buy
50,726
+33,091
+188% +$76.6K ﹤0.01% 2548
2025
Q3 		$38.3K Buy
+17,635
New +$41.6K ﹤0.01% 3039
2025
Q1 		– Sell
-46,417
Closed -$343K – 1701
2024
Q4 		$343K Buy
46,417
+3,266
+8% +$30.3K ﹤0.01% 1573
2024
Q3 		$405K Buy
43,151
+239
+0.6% +$2.26K ﹤0.01% 1492
2024
Q2 		$344K Buy
42,912
+361
+0.8% +$3.87K ﹤0.01% 1525
2024
Q1 		$631K Buy
42,551
+2,678
+7% +$31.2K ﹤0.01% 1398
2023
Q4 		$324K Buy
+39,873
New +$209K ﹤0.01% 1448
2023
Q3 		– Sell
-37,758
Closed -$266K – 1661
2023
Q2 		$266K Buy
37,758
+1,385
+4% +$9.9K ﹤0.01% 1552
2023
Q1 		$221K Buy
36,373
+2,000
+6% +$13.8K ﹤0.01% 1765
2022
Q4 		$219K Buy
34,373
+3,500
+11% +$27.3K ﹤0.01% 1624
2022
Q3 		$295K Sell
30,873
-682
-2% -$7.86K ﹤0.01% 1474
2022
Q2 		$347K Buy
31,555
+8,871
+39% +$116K ﹤0.01% 1413
2022
Q1 		$377K Sell
22,684
-308
-1% -$4.76K ﹤0.01% 1430
2021
Q4 		$438K Buy
22,992
+22,642
+6,469% +$498K ﹤0.01% 1366
2021
Q3 		$8K Sell
350
-150
-30% -$3.53K ﹤0.01% 2992
2021
Q2 		$13K Hold
500
– – ﹤0.01% 2669
2021
Q1 		$15K Hold
500
– – ﹤0.01% 2412
2020
Q4 		$23K Sell
500
-412
-45% -$16.4K ﹤0.01% 1952
2020
Q3 		$30K Buy
912
+49
+6% +$1.5K ﹤0.01% 1655
2020
Q2 		$24K Sell
863
-67
-7% -$2.2K ﹤0.01% 1617
2020
Q1 		$28K Buy
930
+180
+24% +$4.77K ﹤0.01% 1406
2019
Q4 		$21K Buy
+750
New +$17.1K ﹤0.01% 1378
2019
Q2 		– Sell
-82
Closed -$1K – 1802
2019
Q1 		$1K Buy
+82
New +$796 ﹤0.01% 1860

Other funds holding IOVA

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Jane Street
Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return
Jupiter Asset Management
Jupiter Asset Management London, United Kingdom $21.4B AUM 19.74% 1-Year Est. Return

Rockefeller Capital Management's IOVA Position: Q3 2026 in Review

Rockefeller Capital Management reduced its Iovance Biotherapeutics (IOVA) stake by 44% in Q3 2026, selling an estimated $110K and leaving 19,614 shares worth $291K. The position accounts for ﹤0.01% of the portfolio, ranked #2450.

Rockefeller Capital Management first reported a position in IOVA in Q1 2019 and has held it in 26 quarters since. The position peaked at $631K in Q1 2024. 253 funds tracked by Wall St. Rank hold IOVA as of Q3 2026.

  • Rockefeller Capital Management held 19,614 shares of Iovance Biotherapeutics worth $291K as of Q3 2026.
  • Rockefeller Capital Management sold 15,368 Iovance Biotherapeutics shares in Q3 2026, an estimated $110K.
  • Iovance Biotherapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #2450 holding.
  • Rockefeller Capital Management first reported a position in Iovance Biotherapeutics in Q1 2019 and has held it in 26 quarters since.
  • Rockefeller Capital Management's Iovance Biotherapeutics position peaked at $631K in Q1 2024.
  • 253 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2026.

Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.